SVB Securities analyst Mani Foroohar reiterated a Hold rating on Abeona Therapeutics (ABEO – Research Report) on November 3 and set a price target of $5.00. The company’s shares closed last Friday at $3.83.
According to TipRanks, Foroohar is an analyst with an average return of -15.4% and a 39.41% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Moderna, and BridgeBio Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abeona Therapeutics with a $13.50 average price target.
See the top stocks recommended by analysts >>
ABEO market cap is currently $22.79M and has a P/E ratio of -0.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Read More on ABEO:
- Abeona Therapeutics Announces $35 Million Private Placement Financing
- Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Abeona Therapeutics announces database lock for Phase 3 VITAL study of EB-101
- Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Abeona Therapeutics completes patient follow-up in Phase 3 RDEB study
